This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2022 Dec 1;40(34):3903-3906.

doi: 10.1200/JCO.22.01406. Epub 2022 Sep 2.

Ripretinib and the Failure to Advance GI Stromal Tumor Therapy in the Age of Precision Medicine

Gary K Schwartz¹

Affiliations

PMID: 36054848
DOI: 10.1200/JCO.22.01406

Editorial

Ripretinib and the Failure to Advance GI Stromal Tumor Therapy in the Age of Precision Medicine

Gary K Schwartz. J Clin Oncol. 2022.

. 2022 Dec 1;40(34):3903-3906.

doi: 10.1200/JCO.22.01406. Epub 2022 Sep 2.

Author

Gary K Schwartz¹

Affiliation

¹ Columbia University, New York, NY.

PMID: 36054848
DOI: 10.1200/JCO.22.01406

No abstract available

PubMed Disclaimer

Comment on

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
Bauer S, Jones RL, Blay JY, Gelderblom H, George S, Schöffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Su Y, Meade J, Wang T, Sherman ML, Ruiz-Soto R, Heinrich MC. Bauer S, et al. J Clin Oncol. 2022 Dec 1;40(34):3918-3928. doi: 10.1200/JCO.22.00294. Epub 2022 Aug 10. J Clin Oncol. 2022. PMID: 35947817 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.